Children's Hospital is part of the UPMC family.
This Pediatric Brain Tumor Research Consortium trial is studying selumetinib, also known as AZD6244, in treating young patients with brain tumors. Researchers are studying the effects of varying dosage levels for patients ages 12 and up, and for patients under the age of 12. AZD6244 has been studied in adults, however it has not been previously studied in pediatric patients.
Study Level: Phase II
Subject to certain exclusion criteria, this study is open to males and females, ages 3 to 21 years old, who have a brain tumor that is growing or has come back.
Males and Females: Ages 3 to 21 years
Following an initial physical exam, participants will take a selumetinib capsule twice a day over a course of 28 days, for up to 26 courses. At specific intervals, researchers will require other tests, including bloodwork to measure how the study drug is being absorbed into the blood. MRI scans of the brain tumor will also be done after specific intervals.
Duration: Approximately 2 years
Pediatric Brain Tumor Consortium (Study PBTC-029B)
National Cancer Institute
Study Description at National Institutes of Health
A. Kim Ritchey, MD
For more information about the study or enrollment, please contact:
Research Coordinator Angela Connelly, RN, BSN
Children's Hospital's main campus is located in the Lawrenceville neighborhood. Our main hospital address is:
Children’s Hospital of Pittsburgh of UPMC
One Children’s Hospital Way
4401 Penn Ave.
Pittsburgh, PA 15224
In addition to the main hospital, Children's has many convenient locations in other neighborhoods throughout the greater Pittsburgh region.
With myCHP, you can request appointments, review test results, and more.
For questions about a hospital bill call:
To pay your bill online, please visit UPMC's online bill payment system.
Interested in giving to Children's Hospital? Visit Children's Hospital of Pittsburgh Foundation's website to: